TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01804985
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
Study: NCT01804985
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
Study: NCT04132479
Drug: Tinidazole 500mg
Normalized name: TINIDAZOLE 500MG TAB
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg taken orally every 12 hours for 5 days
Study: NCT04132479
Drug: Rabeprazole 20mg
Normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg taken orally every 12 hours for 5 days
Study: NCT04132479
Drug: Amoxicillin 500mg
Normalized name: AMOXICILLIN 500MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg taken orally every 12 hours for 14 days
Study: NCT04132479
Drug: Tinidazole 500mg
Normalized name: TINIDAZOLE 500MG TAB
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg taken orally every 12 hours for 14 days
Study: NCT04132479
Drug: Rabeprazole 20mg
Normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg taken orally every 12 hours for 14 days
Study: NCT01883167
Drug: Febuxostat 40 mg
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40 mg qd
Study: NCT02747004
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02747004
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02747004
Drug: Prophylactic Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00783666
Drug: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic Acid
Study: NCT04587453
Drug: Tralokinumab
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
Study: NCT03019783
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
Study: NCT02895529
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
Study: NCT02895529
Drug: Caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
Study: NCT01622231
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 55 mcg/day, intranasal, 12 weeks
Study: NCT04707508
Drug: Valsartan 80 mg and metformin
Normalized name: valsartan 80 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 80 mg once daily in addition to metformin monotherapy
Study: NCT04707508
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin monotherapy
Study: NCT01493479
Drug: 90Y Ibritumomab tiuxetan
Normalized name: ibritumomab tiuxetan (90Y)
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
Study: NCT02627521
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor administration prior to randomization
Study: NCT01493479
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial.
Study: NCT02663596
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
Study: NCT02327000
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
Study: NCT02327000
Drug: Pregabalin 300mg
Normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
Study: NCT05043233
Drug: Methimazole(MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
Study: NCT00927147
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
Study: NCT02811809
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apalutamide 240 mg (4 60mg tablets) daily
Study: NCT02811809
Drug: IHT
Normalized name: rAAV5-miHTT
DrugBank: AMT-130 (DB16975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 3-month depot 22.5 intramuscular dose
Study: NCT02632877
Drug: Pirfenidone with MODD
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
Study: NCT02632877
Drug: Ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
Study: NCT03056274
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
Study: NCT03056274
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
Study: NCT01286038
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
Study: NCT03500484
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
Study: NCT00705419
Drug: Vicriviroc maleate
Normalized name: maleate
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
Study: NCT00705419
Drug: Vicriviroc maleate
Normalized name: maleate
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
Study: NCT00705419
Drug: Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
Study: NCT01635088
Drug: Mometasone furoate 220
Normalized name: MOMETASONE FUROATE 220MCG ORAL INHL 14
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dry powder inhaler QD for 28-43 days
Study: NCT02471469
Drug: Enzalutamide, 160mg, 40 mg soft capsules, once daily
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
Study: NCT04465942
Drug: (chemo)immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
Study: NCT00079170
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01072942
Drug: Ciprofloxacin (Cipro InhaIe, BAYQ3939)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
Study: NCT01635088
Drug: Mometasone furoate 440
Normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dry powder inhaler QD for 28-43 days
Study: NCT03907215
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg; tablet tor oral use; for single- or repeated dosing
Study: NCT00160212
Drug: Daglutril
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00712504
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
Study: NCT00712504
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
Study: NCT03588338
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For postoperative nausea and vomiting
Study: NCT01984242
Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
Study: NCT04526431
Drug: Dosage Forms Oral
Normalized name: osage orange pollen extract
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
Study: NCT01984242
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
Study: NCT01984242
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
Study: NCT00347542
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06048224
Drug: HS628+MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
Study: NCT06048224
Drug: Actemra +MTX
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
Study: NCT00922584
Drug: sorafenib (Nexavar)
Normalized name: sorafenib Oral Tablet [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
Study: NCT03755466
Drug: Baricitinib, olumiant®
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To examine the effects of baricitinib in RA patients
Study: NCT00007683
Drug: Warfarin titrated to an INR of 2.5-3.0
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
Study: NCT00007683
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
Study: NCT03755466
Drug: Biologics
Normalized name: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
DrugBank: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection (DB16520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the effects of biologics in RA patients
Study: NCT03755466
Drug: Tofacitinib 5 MG [Xeljanz]
Normalized name: tofacitinib 5 MG [Xeljanz]
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To examine the effects of tofacitinib in RA patients
Study: NCT00007683
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
Study: NCT01632709
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one injection of 10ml of .25%
Study: NCT01575522
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01969357
Drug: 100 mg Sitagliptin
Normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
Study: NCT02833038
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
Study: NCT01471990
Drug: Pituitary Adenylate Cyclase-Activating Polypeptide-38
Normalized name: SH-polypeptide-42
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 pmol/kg/min over 20 mins
Study: NCT01471990
Drug: Vasoactive Intestinal Peptide
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 pmol/kg/min over 20 mins
Study: NCT02554864
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT02554864
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT01955304
Drug: fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
Study: NCT03617302
Drug: Experimental: Nitrate-containing
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT03617302
Drug: Placebo: Nitrate-depleted
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04673500
Drug: Propofol lidocaine through large vein
Normalized name: Propofol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
Study: NCT04673500
Drug: Propofol lidocaine through small vein
Normalized name: Propofol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
Study: NCT02625948
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00764114
Drug: antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 12 weeks
Study: NCT02473211
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 mg tablet administered once daily
Study: NCT02473211
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir 60mg tablet administered once daily
Study: NCT00967538
Drug: etanercept 50 mg
Normalized name: etanercept 50 MG/ML
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
Study: NCT03569033
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 45 mg will be administered orally.
Study: NCT02517788
Drug: Interferon beta-1a HSA-free biosimilar
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
Study: NCT00765557
Drug: MiraLAX
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study: NCT03295084
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Escalation
Study: NCT00000371
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/daily by mouth
Study: NCT02517788
Drug: Interferon beta-1a HSA+ biosimilar
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
Study: NCT02517788
Drug: Interferon beta-1a original
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
Study: NCT02296684
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04389632
Drug: sigvotatug vedotin
Normalized name: Sigvotatug vedotin
DrugBank: SGN-B6A (DB18377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered into the vein (IV; intravenously)
Study: NCT04389632
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg every 3 weeks or 400mg every 6 weeks, given by IV
Study: NCT04389632
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 every 3 weeks, given by IV
Study: NCT04389632
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 mg/mL per min every 3 weeks, given by IV
Study: NCT04381429
Drug: A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
Normalized name: A F Green No.2
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
Study: NCT04381429
Drug: F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
Normalized name: Cl-F-Ara-A
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
Study: NCT03141203
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg vial for Injection